Market Overview

CerSci Therapeutics Awarded Phase I STTR Grant From the National Institute of Neurological Disorders and Stroke of the National Institutes of Health to Test Feasibility of a New Therapeutic Approach to Treat Migraine

Share:

CerSci Therapeutics Awarded Phase I STTR Grant From the National Institute of Neurological Disorders and Stroke of the National Institutes of Health to Test Feasibility of a New Therapeutic Approach to Treat Migraine

PR Newswire

DALLAS, Aug. 21, 2018 /PRNewswire/ -- CerSci Therapeutics, a non-opioid drug development firm based in Dallas, Texas has received notice from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) that it has been awarded a Phase I Small Business Technology Transfer (STTR) grant totaling over $220,000. These funds will support the preclinical development of novel, proprietary small-molecules for the treatment of migraine.

Dr. Scott L. Dax, CerSci Chief Scientific Officer, commented that the company is extremely grateful for continued support from the NIH which helps "to fuel the CerSci mission of developing new therapeutics to treat pain by thwarting processes that lead to neuronal sensitization. We are especially thrilled to have Professor Greg Dussor leading this project given his renowned expertise in the area of migraine." 

Professor Dussor, added that "It has been known for over 170 years that nitric oxide-generating drugs like nitroglycerin reliably trigger migraines in humans. This observation strongly suggests a role for nitric oxide and its downstream products in migraine pathology.  The CerSci platform is uniquely positioned to explore nitric oxide-initiated pathways that lead to the onset of migraine, and to develop new drugs to prevent or treat the attacks that afflict and disable millions of people, primarily females." 

"Funding of this proposal further validates the science we conduct at CerSci Therapeutics and will expand our 'footprint' in pain research, as we broaden our pipeline from acute use products to replace opioids, to drugs that will manage chronic neuropathies, and now focus on drugs for migraine," stated CerSci Chief Executive Officer, Dr. Lucas Rodriguez.

This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About CerSci Therapeutics
CerSci Therapeutics is dedicated to pharmaceutical research and development in the area of non-opioid therapeutics for the alleviation of acute and chronic pain.

Media Contact:
Eugene Garza
+1 (214) 306-6218
200483@email4pr.com  
www.CerSci.com

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/cersci-therapeutics-awarded-phase-i-sttr-grant-from-the-national-institute-of-neurological-disorders-and-stroke-of-the-national-institutes-of-health-to-test-feasibility-of-a-new-therapeutic-approach-to-treat-migraine-300700307.html

SOURCE CerSci Therapeutics

View Comments and Join the Discussion!